Recently, Wolf et al. reported that the expression of PGC1α is upregulated, and mitochondrial oxidative phosphorylation is subsequently increased in drug-resistant subpopulations of tumor cells and CSCs [8, 9], suggesting a common molecular strategy shared by highly malignant cancer subtypes in metabolic and genotoxic contexts. Here, PPARGC1A is linked to cancer.